Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency

Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency

Summary: We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Luis Eduardo R. Cunha, Adilson A. Stolet, Marcelo A. Strauch, Victor A.R. Pereira, Carlos H. Dumard, Andre M.O. Gomes, Fábio L. Monteiro, Luiza M. Higa, Patrícia N.C. Souza, Juliana G. Fonseca, Francisco E. Pontes, Leonardo G.R. Meirelles, José W.M. Albuquerque, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Tulio M. Lima, Renata G.F. Alvim, Federico F. Marsili, Marcella Moreira Caldeira, Russolina B. Zingali, Guilherme A.P. de Oliveira, Thiago M.L. Souza, Alexandre S. Silva, Rodrigo Muller, Daniela del Rosário Flores Rodrigues, Luciana Jesus da Costa, Arthur Daniel R. Alves, Marcelo Alves Pinto, Andréa C. Oliveira, Herbert L.M. Guedes, Amilcar Tanuri, Leda R. Castilho, Jerson L. Silva
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Immunology
Equine immunology
Biological sciences
Science
Q
Acceso en línea:https://doaj.org/article/fd393a9b9edf40629a376603a387320c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Summary: We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT) was 1:14,604 (average PRNT90). Plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab’)2 preparation with PRNT90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Challenge studies were carried out in hamsters and showed the in vivo ability of equine F(ab’)2 to reduce viral load in the pulmonary tissues and significant clinical improvement determined by weight gain. The neutralization curve by F(ab’)2 was similar against the WT and P.2 variants, but displaced to higher concentrations by 0.39 log units against the P.1 (Gamma) variant. These results support the possibility of using equine F(ab’)2 preparation for the clinical treatment of COVID patients.

Ejemplares similares